(+)-Epicatechin or ent-Epicatechin is one of the 4 catechin diastereoisomers. (+)-Epicatechin has been isolated from various species of Palmae. It is occurred in the leaves or fruit of six palm species. In addition, it was isolated from Dryas octopetala and guarana seeds. It resists to the microbial transformation by endophytic fungi isolated from a tea plant.

MX-100 (also known as PL-100) is a benzenesulfonamide derivative patented by Pharmacor Inc as HIV aspartyl protease inhibitor. MX-100 retained excellent antiviral activity against almost all of these protease inhibitor-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC50 for MX-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs. Preclinical studies showed that MX-100 possessed suboptimal solubility and pharmacokinetic, (PK) properties, possibly hindering further development. MX-100 successfully completed preclinical and clinical development (phase I in healthy volunteers) and have been licensed to Merck in 2006

Lisavanbulin, also known as BAL-101553, a prodrug of the molecule BAL-27862 with potential antitumor activity. BAL-27862 binds to tubulin, prevents tubulin polymerization, destabilizes microtubules, arrests tumor cell proliferation, and induces cell death in cancer cells. Lisavanbulin participated in phase II clinical trials for the treatment of advanced solid tumors. Besides, the drug participates in a 1/2a clinical study in patients with recurrent glioblastoma and in patients with platinum-resistant or refractory ovarian cancer. In this study, will be characterized the safety and tolerability and to obtain efficacy data in these selected cancer types.

Cenerimod is an orally available sphingosine-1-phosphate receptor 1 (S1P1) modulator that is being developed by Idorsia Pharmaceuticals for the treatment of systemic lupus erythematosus. Sphingosine-1-phosphate (S1P), a lipid mediator, regulates lymphocyte migration between lymphoid tissue and blood. Cenerimod is a potent, selective, safe and orally administrable S1P1 receptor modulator, which reportedly reduced blood lymphocytes and attenuated murine experimental autoimmune encephalomyelitis (EAE) in a murine model. Cenerimod has potential as novel therapy with an improved safety profile for autoimmune diseases with a high unmet medical need.

Mitoglitazone (previously known as MSDC-0160 or CAY-10415) is a mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is modulated MPC and act as insulin sensitizers without activating PPAR gamma. (Mitoglitazone exhibits very low binding affinity and activity at PPARγ). Mitoglitazone has been used in trials phase II studying the treatment of Type 2 Diabetes and Alzheimer's disease; the treatment for diabetes was discontinued. In addition, MSDC-0160 has demonstrated significant neuroprotective effects in the En1+/- mouse model of Parkinson’s disease via modulation of the mTOR-autophagy signaling cascade.

Depramine is a dibenzazepine derivative. Its chemical structure is related to imipramine and it has antidepressant effects as well as anti-Parkinson effects. Dimepramine fumarate is an anticholinergic agent and inhibits the uptake of norepinephrine. The anticataleptic effect of dimepramine fumarate is attributed to its anticholinergic properties and to its probable role in central adrenergic and/or dopaminergic stimulation. The drug tends to decrease autonomic arousal responses of Parkinson patients as measured by resting conductance levels, number of fluctuations in skin conduction per minute, orienting response, and habituation rate. Depramine is used for the treatment of obsessive compulsive disorder, obsessions and phobias, panic disorder, cataplexy associated with narcolepsy, major depressive disorder, and chronic pain. It can help ease the symptoms in each of these conditions. It works by interfering with the brain chemical serotonin. Side effects of depramine are: dizziness, irritability, blurred vision, dry mouth, nausea or vomiting, swelling of face and feet, acid or sour stomach, constipation, shaking of hands or feet, mouth ulcers, irregular menstrual periods.

CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.